BIIB Stock Analysis — Biogen
Sector: Healthcare
AI Verdict
At 12.9x forward earnings and massive expected EPS growth, Biogen looks cheap for the risk if its neurology pipeline delivers, but the overbought RSI warns the market is already betting big on success.
Competitive Moat
Biogen specializes in neurology-focused pharmaceuticals, with a defensible position in multiple sclerosis and Alzheimer's treatments due to deep clinical expertise and a robust patent portfolio. Its pipeline and regulatory know-how create high barriers for competitors in complex CNS drug development.
Summary
A sharp 80.8% jump in forward EPS expectations has slashed Biogen’s forward P/E to 12.9x, drawing attention after a 72.49% one-year run.
Where It Stands
Biogen is up 72.49% over the past year, trades at 12.9x next year's earnings versus the healthcare median of 22x, and its RSI of 73.2 signals overbought territory.
Key Metrics
- RSI: 73.2 — Overbought
- Trailing P/E: 23.3x
- Forward P/E: 12.9x
- PEG Ratio: 0.29
- Earnings Growth: +0.8%
- Revenue Growth: +0.0%
- Market Cap: $32.0B
- 1-Year Return: 72.49%
- 52-Week High: $218.06
- 52-Week Low: $121.05
Analyst Consensus
27 Buy · 16 Hold · 1 Sell (44 analysts)
Bull Case
Forward EPS is expected to surge 80.8% while the stock trades at just 12.9x those earnings, making it cheap for the growth on offer if Biogen’s neurology franchise delivers.
Bear Case
With an RSI of 73.2, a pullback to neutral (RSI 60) could easily erase a chunk of recent gains, especially if the 80.8% EPS growth doesn’t materialize.
Catalyst to Watch
Watch for clinical trial readouts or regulatory decisions on new neurology drugs, as these will determine if the 80.8% earnings growth forecast holds up.